Market Place
Sourcing Support
Cara Therapeutics discontinues neurological condition study as drug fails
13 Jun 2024 //
REUTERS
Cara Therapeutics Announces Outcome Of KOURAGE-1 Study Part A
12 Jun 2024 //
GLOBENEWSWIRE
Cara Announces Outcome from Dose-Finding Part A of Evaluating Difelikefalin
18 Dec 2023 //
GLOBENEWSWIRE
Kapruvia recommended by NICE for the treatment of CKD-associated pruritus
19 May 2023 //
PR NEWSWIRE
Kapruvi (difelikefalin) recommended by England NICE
18 May 2023 //
GLOBENEWSWIRE
Cara Therapeutics Announces Difelikefalin (KORSUVA®) InjectionNDA
28 Sep 2022 //
GLOBENEWSWIRE
Cara`s Presents Late-Breaking Results Ph 2 Trial of Oral Difelikefalin
08 Sep 2022 //
GLOBENEWSWIRE
Kapruvia approved in Switzerland with additional regulatory decisions
19 Aug 2022 //
GLOBENEWSWIRE
Cara Tx`s Positive Topline Results from KOMFORT PII Trial of Oral Difelikefalin
30 Jun 2022 //
GLOBENEWSWIRE
Vifor Fresenius Generic Kapruvia (difelikefalin) Receives Approval in Europe
28 Apr 2022 //
EMA
Kapruvia approved by EC for moderate-to-severe pruritus in hemodialysis
28 Apr 2022 //
BUSINESSWIRE
Cara Therapeutics Shows Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA
04 Apr 2022 //
GLOBENEWSWIRE
Cara Tx Announces Oral KORSUVA Shows Improvement in Atopic Dermatitis
28 Mar 2022 //
PRESS RELEASE
Kapruvia receives positive CHMP opinion for pruritus in hemodialysis patients
28 Feb 2022 //
BUSINESSWIRE
Cara Therapeutics to Host Virtual R&D Day on March 11, 2022
18 Feb 2022 //
GLOBENEWSWIRE
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™
20 Dec 2021 //
GLOBENEWSWIRE
Enteris BioPharma, Receives $5M Milestone Payment from Cara Therapeutics
09 Dec 2021 //
PRNEWSWIRE
Cara, Vifor win FDA nod for pruritis treatment Korsuva
24 Aug 2021 //
FIERCEPHARMA
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™
20 Oct 2020 //
BUSINESSWIRE
VFMCRP & Cara Therapeutics announce +ve results global KALM-2 pivotal ph-III
20 Apr 2020 //
BUSINESSWIRE
Cara Therapeutics, Announces Top Line Data from Phase 2 Trial of Peptelligence
06 Dec 2019 //
PR NEWSWIRE
Licensing agreement formalizes drug delivery technology partnership
28 Aug 2019 //
IN-PHARMATECHNOLOGIST
Enteris, Cara Therapeutics Enter Peptelligence Pact
27 Aug 2019 //
CONTRACT PHARMA
Cara Therapeutics, Initiates Phase 2 Trial of Peptelligence
11 Jul 2019 //
PR NEWSWIRE
Cara Therapeutics Doses First Pt in Ph 2 Trial of KORSUVA
19 Jul 2018 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.